I recently submitted my PhD dissertation titled "Illiberalism Beyond Borders. Dissecting Russian and Turkish External Influence in Bosnia and Georgia" at @FU_Berlin. Interested in what I found? Read this thread ⬇️
More from Science
✅ I cover the bogus science behind PCR testing, explaining from a lab science point of view why no PCR instrument can “quantify” anything,
[M. Adams]
1. whether it’s a coronavirus viral load or the percentage of a food that’s GMO. In fact, literally all the tests currently conducted with PCR equipment are scientifically invalid when it comes to diagnosing illness or determining infectiousness. The sample acquisition used for
2. PCR tests — nasal swabs — aren’t even standardized! (100% bogus junk science).
After covering PCR tests, today’s update then goes into detail about Director of National Intelligence (DNI) John Ratcliffe, pointing out that he will be issuing a report on foreign interference
3. in U.S. elections on or before Dec. 18th. If this report confirms the existence of foreign interference that was capable of altering the outcome of the election, it gives President Trump full justification to declare the election null and void and dispatch military troops
4. to seize all ballots and hold a new count under military authority.
👉 Podcast notes and sources:
The office of military commissions has cleared its calendar for December:
https://t.co/u4nFRiUj8m
US military STOCKPILED Pfizer’s mRNA vaccineBEFORE it was approved by theFDA
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):
1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.
😭
The new answer to a 77-year-old problem in data analysis, published today in @naturemethods. Instead of significance tests, use estimation graphics. Our software suite DABEST makes it easy for everyone to visualize effect sizes.https://t.co/UzwXJ7EUC5 pic.twitter.com/VtxyY0xaRM
— Adam Claridge-Chang (@adamcchang) June 19, 2019
https://t.co/hm9NoaU4nr
Open letter to journal editors: dynamite plots must die. Dynamite plots, also known as bar and line graphs, hide important information. Editors should require authors to show readers the data and avoid these plots. https://t.co/0GNKEIUCJL pic.twitter.com/OS9ytEFRZN
— Rafael Irizarry (@rafalab) February 22, 2019
https://t.co/8fKDiKjSWc
Couldn't find D3 code for grouped horisontal box plots that show data points so I made this @mbostock @thisisalfie https://t.co/cQjDPhyZdw pic.twitter.com/y6RNmDB2p3
— Ulrik Lyngs (@ulyngs) June 28, 2017
https://t.co/jkaicC1F2x
made a pkg for pirate plots in ggplot: add any of points/means/bars/CIs/violins \u2013 better than ye olde bar/box plotshttps://t.co/Z2m2kW3hsl pic.twitter.com/npAirPQexM
— Mika Braginsky (@mbraginsky) September 28, 2017
https://t.co/PpxWT4Jef4
See the new #PowerBI visual awesomeness for data points & sources, box-&-whisker plots! https://t.co/dOmgoxWfDE pic.twitter.com/HAUOAMJEJW
— Microsoft Power BI (@MSPowerBI) February 1, 2016
You May Also Like
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the
chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project
starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".
P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!
https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?